NBIX:NGS-Neurocrine Biosciences Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 137.83

Change

-3.33 (-2.36)%

Market Cap

USD 4.26B

Volume

1.17M

Analyst Target

USD 140.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

N/A

USD 13.36B
ITCI Intracellular Th

N/A

USD 7.72B
LNTH Lantheus Holdings Inc

N/A

USD 4.49B
ALKS Alkermes Plc

N/A

USD 4.18B
ALVO Alvotech

N/A

USD 3.96B
HCM HUTCHMED DRC

N/A

USD 3.23B
INDV Indivior PLC Ordinary Shares

N/A

USD 2.93B
EVO Evotec SE ADR

N/A

USD 2.51B
AMPH Amphastar P

N/A

USD 2.01B
SUPN Supernus Pharmaceuticals Inc

N/A

USD 1.65B

ETFs Containing NBIX

IBRN iShares Trust - iShares N.. 4.83 % 0.00 %

N/A

USD 3.84M
XYLP:LSE Global X S&P 500® Covere.. 4.19 % 0.00 %

N/A

USD 0.01B
FBT First Trust NYSE Arca Bio.. 3.57 % 0.57 %

N/A

USD 1.08B
JSMD Janus Henderson Small/Mid.. 3.23 % 0.50 %

N/A

USD 0.34B
BBP Virtus LifeSci Biotech Pr.. 2.39 % 0.79 %

N/A

USD 0.02B
HEAL:SW iShares Healthcare Innova.. 1.84 % 0.00 %

N/A

N/A
HSMV First Trust Horizon Manag.. 0.66 % 0.00 %

N/A

USD 0.02B
AGED:SW iShares Ageing Population.. 0.63 % 0.00 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

USD 0.23B
QGRO American Century U.S. Qua.. 0.00 % 0.00 %

N/A

USD 0.89B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

USD 0.50B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.50B
2B77:XETRA iShares Ageing Population.. 0.00 % 0.00 %

N/A

USD 0.50B
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.61% 62% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.61% 62% D 62% D
Trailing 12 Months  
Capital Gain 41.95% 80% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.95% 80% B- 84% B
Trailing 5 Years  
Capital Gain 56.45% 84% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.45% 84% B 72% C
Average Annual (5 Year Horizon)  
Capital Gain 6.26% 65% D 65% D
Dividend Return 6.26% 65% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.40% 93% A 76% C+
Risk Adjusted Return 30.71% 86% B+ 67% D+
Market Capitalization 4.26B 99% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.26 20% 19%
Price/Book Ratio 6.30 18% 18%
Price / Cash Flow Ratio 36.09 5% 8%
Price/Free Cash Flow Ratio 37.62 4% 6%
Management Effectiveness  
Return on Equity 12.68% 87% 81%
Return on Invested Capital 7.88% 81% 75%
Return on Assets 8.78% 90% 93%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.